Table 2.

mAbs with plasma PK following SC administration. Estimated drug-specific parameters ($C{L}_{\mathit{\text{LymCap}}}^{SC}$ and $S_{\mathit{\text{LymUpt}}}^{SC}$) in SC tissue site model using SC PK data are also shown for each mAb

mAb (abbreviation)	Dosing	Ref.	$C{L}_{\mathit{\text{LymCap}}}^{SC}$ (RSE%) (ml/day)	$S_{\mathit{\text{LymUpt}}}^{SC}$ (RSE%)
Adalimumab (Ada)	40 mg	[88]	0.957 (9.5)	0.166 (4.6)
Belimumab (Bel)	200, 240 mg	[70]	0.501 (15)	0.204 (3.9)
Canakinumab (Can)	150, 300 mg	[71]	0.798 (11)	0.220 (5.8)
Daclizumab (Dac)	50, 150, 300 mg	[72]	0.469 (17)	0.0904 (3.7)
Enokizumab (Eno)	1, 3, 9 mg/kg	[73]	0.441 (20)	0.301 (5.0)
Gevokizumab (Gev)	0.03, 0.3 mg/kg	[75]	0.732 (22)	0.130 (7.5)
Golimumab (Gol)	100 mg	[77]	2.72 (8.1)	0.193 (7.5)
Guselkumab (Gus)	10, 30, 100, 300 mg	[78]	3.66 (5.0)	0.283 (5.1)
Infliximab (Inf)	120 mg	[89]	0.950 (15)	0.262 (8.6)
Mepolizumab (Mep)	250 mg	[80]	0.700 (14)	0.272 (5.9)
Risankizumab (Ris)	18, 90, 300mg	[82]	1.38 (9.0)	0.217 (5.6)
Tralokinumab (Tral)	150, 300 mg	[85]	1.69 (7.4)	0.186 (5.2)